Diagnostic and therapeutic biomarkers in glioblastoma: Current status and future perspectives

BioMed Research International

Volumn 2017, Issue , 2017, Pages

  Szopa, Wojciech ^a   Burley, Thomas A ^b   Kramer Marek, Gabriela ^b   Kaspera, Wojciech ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE INHIBITOR 2A; GROWTH FACTOR RECEPTOR; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN MDM2; PROTEIN P14; PROTEIN P53; PROTEIN TYROSINE KINASE; DNA LIGASE; DNA METHYLTRANSFERASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR VIII; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN; MGMT PROTEIN, HUMAN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL PRACTICE; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENE REARRANGEMENT; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NEXT GENERATION SEQUENCING; PHENOTYPE; PI3K/AKT SIGNALING; PROMOTER REGION; REVIEW; TREATMENT FAILURE; TUMOR MICROENVIRONMENT; WORLD HEALTH ORGANIZATION; ADULT; BRAIN NEOPLASMS; DNA METHYLATION; DRUG THERAPY; FEMALE; GENE DELETION; GENETICS; IMMUNE SYSTEM; MALE; MIDDLE AGED; MUTATION; ONCOLOGY; PROCEDURES; PROGNOSIS; SIGNAL TRANSDUCTION; TRENDS; TUMOR RECURRENCE;

ADULT; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GENE DELETION; GLIOBLASTOMA; HUMANS; IMMUNE SYSTEM; ISOCITRATE DEHYDROGENASE; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; PHENOTYPE; PROGNOSIS; PROMOTER REGIONS, GENETIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 85017554924     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2017/8013575     Document Type: Review

References (141)

1. Q. T. Ostrom, P. M. De Blank, C. Kruchko et al., "Alex's Lemonade stand foundation infant and childhood primary brain and central nervous system tumors diagnosed in the United States in 2007-2011," Neuro-Oncology, vol. 16, supplement 10, pp. x1- x36, 2015.
2. M. L. Affronti, C. R. Heery, J. E. Herndon II et al., "Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy," Cancer, vol. 115, no. 15, pp. 3501-3511, 2009.
3. B. J. Theeler and M. R. Gilbert, "Advances in the treatment of newly diagnosed glioblastoma," BMC Medicine, vol. 13, article 293, 2015.
4. W. Taal, H. M. Oosterkamp, A.M. E. Walenkamp et al., "Singleagent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial," The Lancet Oncology, vol. 15, no. 9, pp. 943-953, 2014.
5. K. Aldape, G. Zadeh, S. Mansouri, G. Reifenberger, and A. von Deimling, "Glioblastoma: pathology, molecular mechanisms andmarkers," Acta Neuropathologica, vol. 129, no. 6, article 1432, pp. 829-848, 2015.
6. S. K. Carlsson, S. P. Brothers, and C. Wahlestedt, "Emerging treatment strategies for glioblastoma multiforme," EMBO Molecular Medicine, vol. 6, no. 11, pp. 1359-1370, 2014.
7. D. N. Louis, H. Ohgaki, O. D. Wiestler et al., "The 2007 WHO classification of tumours of the central nervous system," Acta Neuropathologica, vol. 114, no. 2, pp. 97-109, 2007.
8. D. N. Louis, A. Perry, G. Reifenberger et al., "The 2016World Health Organization Classification of Tumors of the Central Nervous System: a summary," Acta Neuropathologica, vol. 131, no. 6, pp. 803-820, 2016.
9. H. Ohgaki and P. Kleihues, "The definition of primary and secondary glioblastoma," Clinical Cancer Research, vol. 19, no. 4, pp. 764-772, 2013.
10. H. Ohgaki, P. Dessen, B. Jourde et al., "Genetic pathways to glioblastoma: a population-based study," Cancer Research, vol. 64, no. 19, pp. 6892-6899, 2004.
11. M. Nakamura, T. Watanabe, Y. Yonekawa, P. Kleihues, and H. Ohgaki, "Promoter methylation of theDNArepair geneMGMT in astrocytomas is frequently associated with G:C → A:T mutations of the TP53 tumor suppressor gene," Carcinogenesis, vol. 22, no. 10, pp. 1715-1719, 2001.
12. H. Yan, D.W. Parsons, G. Jin et al., "IDH1 and IDH2 mutations in gliomas," New England Journal of Medicine, vol. 360, no. 8, pp. 765-773, 2009.
13. H. S. Phillips, S. Kharbanda, R. Chen et al., "Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis," Cancer Cell, vol. 9, no. 3, pp. 157-173, 2006.
14. R. G. W. Verhaak, K. A. Hoadley, E. Purdom et al., "Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1," Cancer Cell, vol. 17, no. 1, pp. 98-110, 2010.
15. C. W. Brennan, R. G. Verhaak, A. McKenna et al., "The somatic genomic landscape of glioblastoma," Cell, vol. 155, no. 2, pp. 462-477, 2013.
16. J. Wang, H.-K. Su, H.-F. Zhao, Z.-P. Chen, and S.-S. T. To, "Progress in the application of molecular biomarkers in gliomas," Biochemical and Biophysical Research Communications, vol. 465, no. 1, pp. 1-4, 2015.
17. J. T. Huse and E. C. Holland, "Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma," Nature Reviews Cancer, vol. 10, no. 5, pp. 319-331, 2010.
18. A. Sottoriva, I. Spiteri, S. G. M. Piccirillo et al., "Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics," Proceedings of the National Academy of Sciences of theUnited States ofAmerica, vol. 110, no. 10, pp.4009-4014, 2013.
19. T. R. Jue and K. L. McDonald, "The challenges associated with molecular targeted therapies for glioblastoma," Journal of Neuro-Oncology, vol. 127, no. 3, pp. 427-434, 2016.
20. G. Farias-Eisner, A. M. Bank, B. Y. Hwang et al., "Glioblastoma biomarkers from bench to bedside: advances and challenges," British Journal of Neurosurgery, vol. 26, no. 2, pp. 189-194, 2012.
21. K. P. L. Bhat, V. Balasubramaniyan, B. Vaillant et al., "Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma," Cancer Cell, vol. 24, no. 3, pp. 331- 346, 2013.
22. P. Mao, K. Joshi, J. Li et al., "Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3," Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 21, pp. 8644-8649, 2013.
23. I. Nakano, "Stem cell signature in glioblastoma: therapeutic development for a moving target," Journal of Neurosurgery, vol. 122, no. 2, pp. 324-330, 2015.
24. R. Chakrabarti, J. Hwang, M. Andres Blanco et al., "Elf5 inhibits the epithelial-mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2," Nature Cell Biology, vol. 14, no. 11, pp. 1212-1222, 2012.
25. D. J. Aum, D. H. Kim, T. L. Beaumont, E. C. Leuthardt, G. P. Dunn, and A. H. Kim, "Molecular and cellular heterogeneity: the hallmark of glioblastoma," Neurosurgical Focus, vol. 37, no. 6, article E11, 2014.
26. P. Y. Wen and S. Kesari, "Malignant gliomas in adults," New England Journal of Medicine, vol. 359, no. 5, pp. 492-507, 2008.
27. F. B. Furnari, T. Fenton, R. M. Bachoo et al., "Malignant astrocytic glioma: genetics, biology, and paths to treatment," Genes and Development, vol. 21, no. 21, pp. 2683-2710, 2007.
28. H. Ohgaki and P. Kleihues, "Genetic alterations and signaling pathways in the evolution of gliomas," Cancer Science, vol. 100, no. 12, pp. 2235-2241, 2009.
29. I. K. Mellinghoff, M. Y. Wang, I. Vivanco et al., "Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors," The New England Journal of Medicine, vol. 353, no. 19, pp. 2012-2024, 2005.
30. E. Padfield, H. P. Ellis, and K.M. Kurian, "Current therapeutic advances targeting EGFR and EGFRvIII in glioblastoma," Frontiers in Oncology, vol. 5, article no. 5, 2015.
31. F. B. Furnari, T. F. Cloughesy, W. K. Cavenee, and P. S. Mischel, "Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma," Nature Reviews Cancer, vol. 15, no. 5, pp. 302-310, 2015.
32. J. Hobbs, M. N. Nikiforova, D. W. Fardo et al., "Paradoxical relationship between the degree of EGFR amplification and outcome in glioblastomas," The American Journal of Surgical Pathology, vol. 36, no. 8, pp. 1186-1193, 2012.
33. M. Weller, K. Kaulich, B. Hentschel et al., "Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy," International Journal of Cancer, vol. 134, no. 10, pp. 2437-2447, 2014.
34. C. E. Pelloski, K. V. Ballman, A. F. Furth et al., "Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma," Journal of Clinical Oncology, vol. 25, no. 16, pp. 2288-2294, 2007.
35. C. Faulkner, A. Palmer, H. Williams et al., "EGFR and EGFRvIII analysis in glioblastoma as therapeutic biomarkers," British Journal of Neurosurgery, vol. 29, no. 1, pp. 23-29, 2015.
36. A. B. Heimberger, R. Hlatky, D. Suki et al., "Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients," Clinical Cancer Research, vol. 11, no. 4, pp. 1462-1466, 2005.
37. D. A. Haas-Kogan, M. D. Prados, T. Tihan et al., "Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib," Journal of the National Cancer Institute, vol. 97, no. 12, pp. 880-887, 2005.
38. A. M. P. Omuro, S. Faivre, and E. Raymond, "Lessons learned in the development of targeted therapy for malignant gliomas," Molecular CancerTherapeutics, vol. 6, no. 7, pp. 1909-1919, 2007.
39. E. Franceschi, G. Cavallo, S. Lonardi et al., "Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)," British Journal of Cancer, vol. 96, no. 7, pp. 1047-1051, 2007.
40. C. Alifieris andD. T. Trafalis, "Glioblastomamultiforme: pathogenesis and treatment," Pharmacology andTherapeutics, vol. 152, pp. 63-82, 2015.
41. S. Sathornsumetee, D. A. Reardon, A. Desjardins, J. A. Quinn, J. J. Vredenburgh, and J. N. Rich, "Molecularly targeted therapy for malignant glioma," Cancer, vol. 110, no. 1, pp. 13-24, 2007.
42. C. A. Del Vecchio, C. P. Giacomini, H. Vogel et al., "EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms," Oncogene, vol. 32, no. 21, pp. 2670-2681, 2013.
43. N. Shinojima, K. Tada, S. Shiraishi et al., "Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme," Cancer Research, vol. 63, no. 20, pp. 6962-6970, 2003.
44. N. Montano, T. Cenci, M. Martini et al., "Expression of EGFRvIII in glioblastoma: prognostic significance revisited," Neoplasia, vol. 13, no. 12, pp. 1113-1121, 2011.
45. R. Chen, A. L. Cohen, and H. Colman, "Targeted therapeutics in patients with high-grade gliomas: past, present, and future," Current Treatment Options in Oncology, vol. 17, no. 8, article no. 42, 2016.
46. X. Li, C. Wu, N. Chen et al., "PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma," Oncotarget, vol. 7, no. 22, pp. 33440-33450, 2016.
47. A. Sami and M. Karsy, "Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding," Tumor Biology, vol. 34, no. 4, pp. 1991-2002, 2013.
48. M. Nakada, D. Kita, T. Watanabe et al., "Aberrant signaling pathways in Glioma," Cancers, vol. 3, no. 3, pp. 3242-3278, 2011.
49. D. A. Reardon, G. Dresemann, S. Taillibert et al., "Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma," British Journal of Cancer, vol. 101, no. 12, pp. 1995-2004, 2009.
50. D. Singh, J. M. Chan, P. Zoppoli et al., "Transforming fusions of FGFR and TACC genes in human glioblastoma," Science, vol. 337, no. 6099, pp. 1231-1235, 2012.
51. R. Abounader and J. Laterra, "Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis," Neuro- Oncology, vol. 7, no. 4, pp. 436-451, 2005.
52. J. T. Huse and K. D. Aldape, "The evolving role of molecular markers in the diagnosis and management of diffuse glioma," Clinical Cancer Research, vol. 20, no. 22, pp. 5601-5611, 2014.
53. Cancer Genome Atlas Research Network, "Comprehensive genomic characterization defines human glioblastoma genes and core pathways," Nature, vol. 455, no. 7216, pp. 1061-1068, 2008.
54. A. Joy, A. Ramesh, I. Smirnov et al., "AKT pathway genes define 5 prognostic subgroups in glioblastoma," PLoS ONE, vol. 9, no. 7, Article ID e100827, 2014.
55. D.W. Parsons, S. Jones, X. Zhang et al., "An integrated genomic analysis of human glioblastoma multiforme," Science, vol. 321, no. 5897, pp. 1807-1812, 2008.
56. K. H. Vousden and D. P. Lane, "p53 in health and disease," Nature ReviewsMolecular Cell Biology, vol. 8, no. 4, pp. 275-283, 2007.
57. O. Bögler, H.-J. S. Huang, P. Kleihues, andW. K. Cavenee, "The p53 gene and its role in human brain tumors," Glia, vol. 15, no. 3, pp. 308-327, 1995.
58. C. Gomez-Manzano, J. Fueyo, A. P. Kyritsis et al., "Adenovirusmediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis," Cancer Research, vol. 56, no. 4, pp. 694-699, 1996.
59. H. Ohgaki and P. Kleihues, "Genetic pathways to primary and secondary glioblastoma," American Journal of Pathology, vol. 170, no. 5, pp. 1445-1453, 2007.
60. F. J. Stott, S. Bates, M. C. James et al., "The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 andMDM2," EMBO Journal, vol. 17, no. 17, pp. 5001-5014, 1998.
61. C. J. Sherr and J. M. Roberts, "CDK inhibitors: positive and negative regulators of G1-phase progression," Genes and Development, vol. 13, no. 12, pp. 1501-1512, 1999.
62. C. L. Appin and D. J. Brat, "Molecular pathways in gliomagenesis and their relevance to neuropathologic diagnosis," Advances in Anatomic Pathology, vol. 22, no. 1, pp. 50-58, 2015.
63. M.N. T. Thuy, J. K. T. Kam, G. C. Y. Lee et al., "Anovel literaturebased approach to identify genetic and molecular predictors of survival in glioblastoma multiforme: analysis of 14, 678 patients using systematic review and meta-analytical tools," Journal of Clinical Neuroscience, vol. 22, no. 5, pp. 785-799, 2015.
64. X. Xu, J. Zhao, Z. Xu et al., "Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel selfregulatory mechanism of activity," Journal of Biological Chemistry, vol. 279, no. 32, pp. 33946-33957, 2004.
65. Z. J. Reitman and H. Yan, "Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism," Journal of the National Cancer Institute, vol. 102, no. 13, pp. 932-941, 2010.
66. L. Dang, D. W. White, S. Gross et al., "Cancer-associated IDH1 mutations produce 2-hydroxyglutarate," Nature, vol. 462, no. 7274, pp. 739-744, 2009.
67. W. Xu, H. Yang, Y. Liu et al., "Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases," Cancer Cell, vol. 19, no. 1, pp. 17-30, 2011.
68. N. K. Kloosterhof, L. B. Bralten, H. J. Dubbink, P. J. French, and M. J. van den Bent, "Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?" The Lancet Oncology, vol. 12, no. 1, pp. 83-91, 2011.
69. S. Zhao, Y. Lin, W. Xu et al., "Glioma-derivedmutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1α," Science, vol. 324, no. 5924, pp. 261-265, 2009.
70. S. Nobusawa, T. Watanabe, P. Kleihues, and H. Ohgaki, "IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas," Clinical Cancer Research, vol. 15, no. 19, pp. 6002-6007, 2009.
71. K. Ichimura, D. M. Pearson, S. Kocialkowski et al., "IDH1 mutations are present in themajority of common adult gliomas but rare in primary glioblastomas," Neuro-Oncology, vol. 11, no. 4, pp. 341-347, 2009.
72. C. G. Duncan, B. G. Barwick, G. Jin et al., "A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation," Genome Research, vol. 22, no. 12, pp. 2339- 2355, 2012.
73. H. Noushmehr, D. J. Weisenberger, K. Diefes et al., "Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma," Cancer Cell, vol. 17, no. 5, pp. 510- 522, 2010.
74. S. Turcan, D. Rohle, A. Goenka et al., "IDH1mutation is sufficient to establish the glioma hypermethylator phenotype," Nature, vol. 483, no. 7390, pp. 479-483, 2012.
75. M. Nakamura, Y. Yonekawa, P. Kleihues, and H. Ohgaki, "Promoter hypermethylation of the RB1 gene in glioblastomas," Laboratory Investigation, vol. 81, no. 1, pp. 77-82, 2001.
76. M. Weller, S. M. Pfister, W. Wick, M. E. Hegi, G. Reifenberger, and R. Stupp, "Molecular neuro-oncology in clinical practice: a new horizon," The Lancet Oncology, vol. 14, no. 9, pp. e370-e379, 2013.
77. J. Beiko, D. Suki, K. R. Hess et al., "IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection," Neuro-Oncology, vol. 16, no. 1, pp. 81-91, 2014.
78. J.-R. Chen, Y. Yao, H.-Z. Xu, and Z.-Y. Qin, "Isocitrate dehydrogenase (IDH)1/2 mutations as prognostic markers in patients with glioblastomas," Medicine (Baltimore), vol. 95, no. 9, Article ID e2583, 2016.
79. D. Rohle, J. Popovici-Muller, N. Palaskas et al., "An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells," Science, vol. 340, no. 6132, pp. 626-630, 2013.
80. Y.-S. Keum and B. Y. Choi, "Isocitrate dehydrogenase mutations: new opportunities for translational research," BMB Reports, vol. 48, no. 5, pp. 266-270, 2015.
81. F. Wang, J. Travins, B. DeLaBarre et al., "Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation," Science, vol. 340, no. 6132, pp. 622-626, 2013.
82. J. Popovici-Muller, J. O. Saunders, F. G. Salituro et al., "Discovery of the first potent inhibitors of mutant IDH1 that lower tumor 2-HG in vivo," ACS Medicinal Chemistry Letters, vol. 3, no. 10, pp. 850-855, 2012.
83. M. E. Hegi, A.-C. Diserens, T. Gorlia et al., "MGMT gene silencing and benefit fromtemozolomide in glioblastoma," New England Journal ofMedicine, vol. 352, no. 10, pp. 997-1003, 2005.
84. I. Zawlik, S. Vaccarella, D. Kita, M. Mittelbronn, S. Franceschi, and H. Ohgaki, "Promoter methylation and polymorphisms of the MGMT gene in glioblastomas: a population-based study," Neuroepidemiology, vol. 32, no. 1, pp. 21-29, 2009.
85. M. Esteller, J. Garcia-Foncillas, E. Andion et al., "Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents," The New England Journal of Medicine, vol. 343, no. 19, pp. 1350-1354, 2000.
86. M. F. Paz, R. Yaya-Tur, I. Rojas-Marcos et al., "CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas," Clinical Cancer Research, vol. 10, no. 15, pp. 4933-4938, 2004.
87. M. Cominelli, S. Grisanti, S. Mazzoleni et al., "EGFR amplified and overexpressing glioblastomas and association with better response to adjuvant metronomic temozolomide," Journal of the National Cancer Institute, vol. 107, no. 5, Article IDdjv041, 2015.
88. W. Wick, M. Platten, C. Meisner et al., "Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial," The Lancet Oncology, vol. 13, no. 7, pp. 707-715, 2012.
89. G. Reifenberger, B. Hentschel, J. Felsberg et al., "Predictive impact of MGMT promoter methylation in glioblastoma of the elderly," International Journal of Cancer, vol. 131, no. 6, pp. 1342- 1350, 2012.
90. A. Malmström, B. H. Grønberg, C. Marosi et al., "Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial," The Lancet Oncology, vol. 13, no. 9, pp. 916-926, 2012.
91. T. S. Armstrong, J. S. Wefel, M. Wang et al., "Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma," Journal of Clinical Oncology, vol. 31, no. 32, pp. 4076-4084, 2013.
92. B. Wiestler, R. Claus, S. A. Hartlieb et al., "Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective," Neuro-Oncology, vol. 15, no. 8, pp. 1017-1026, 2013.
93. M. Weller, G. Tabatabai, B. Kästner et al., "MGMT promoter methylation is a strong prognostic biomarker for benefit fromdose-intensified temozolomide rechallenge in progressive Glioblastoma: the DIRECTOR Trial," Clinical Cancer Research, vol. 21, no. 9, pp. 2057-2064, 2015.
94. B. D. Liebelt, T. Shingu, X. Zhou, J. Ren, S. A. Shin, and J. Hu, "Glioma stemcells: signaling, microenvironment, and therapy," Stem Cells International, vol. 2016, Article ID 7849890, 10 pages, 2016.
95. M. F. Krummel and J. P. Allison, "CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells," Journal of ExperimentalMedicine, vol. 183, no. 6, pp. 2533-2540, 1996.
96. A. K. S. Salama and F. S. Hodi, "Cytotoxic T-lymphocyteassociated antigen-4," Clinical Cancer Research, vol. 17, no. 14, pp. 4622-4628, 2011.
97. O. Bloch, C. A. Crane, R. Kaur, M. Safaee, M. J. Rutkowski, and A. T. Parsa, "Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages," Clinical Cancer Research, vol. 19, no. 12, pp. 3165-3175, 2013.
98. A. T. Parsa, J. S. Waldron, A. Panner et al., "Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma," Nature Medicine, vol. 13, no. 1, pp. 84-88, 2007.
99. T. Doucette, G. Rao, A. Rao et al., "Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas," Cancer Immunology Research, vol. 1, no. 2, pp. 112-122, 2013.
100. A. S. Berghoff, B. Kiesel, G. Widhalm et al., "Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma," Neuro-Oncology, vol. 17, no. 8, pp. 1064-1075, 2015.
101. Y. Liu, R. Carlsson, M. Ambjørn et al., "PD-L1 expression by neurons nearby tumors indicates better prognosis in glioblastoma patients, "The Journal of Neuroscience, vol. 33, no. 35, pp. 14231-14245, 2013.
102. E. K. Nduom, J. Wei, N. K. Yaghi et al., "PD-L1 expression and prognostic impact in glioblastoma," Neuro-Oncology, vol. 18, no. 2, pp. 195-205, 2016.
103. C. Robert, G. V. Long, B. Brady et al., "Nivolumab in previously untreated melanoma without BRAF mutation," The New England Journal of Medicine, vol. 372, no. 4, pp. 320-330, 2015.
104. C. Robert, L. Thomas, I. Bondarenko et al., "Ipilimumab plus dacarbazine for previously untreated metastatic melanoma," The New England Journal ofMedicine, vol. 364, no. 26, pp. 2517- 2526, 2011.
105. F. S. Hodi, S. J. O'Day, D. F. McDermott et al., "Improved survival with ipilimumab in patients with metastatic melanoma," New England Journal of Medicine, vol. 363, no. 8, pp. 711-723, 2010.
106. N. K. Gerber, R. J. Young, C. A. Barker et al., "Ipilimumab and whole brain radiation therapy for melanoma brain metastases," Journal of Neuro-Oncology, vol. 121, no. 1, pp. 159-165, 2015.
107. S. Tanaka, D. N. Louis, W. T. Curry, T. T. Batchelor, and J. Dietrich, "Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?" Nature Reviews Clinical Oncology, vol. 10, no. 1, pp. 14-26, 2013.
108. B. Fong, R. Jin, X. Wang et al., "Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients," PLoS ONE, vol. 7, no. 4, Article ID e32614, 2012.
109. R. F. Barajas Jr., J. S. Chang, M. R. Segal et al., "Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusionMR imaging," Radiology, vol. 253, no. 2, pp. 486-496, 2009.
110. L. S. Hu, L. C. Baxter, K. A. Smith et al., "Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusionMR imagingmeasurements," American Journal ofNeuroradiology, vol. 30, no. 3, pp. 552-558, 2009.
111. H. J. Baek, H. S. Kim, N. Kim, Y. J. Choi, and Y. J. Kim, "Percent change of perfusion skewness and kurtosis: a potential imaging biomarker for early treatment response in patients with newly diagnosed glioblastomas," Radiology, vol. 264, no. 3, pp. 834- 843, 2012.
112. C. Choi, S. K. Ganji, R. J. DeBerardinis et al., "2-Hydroxyglutarate detection by magnetic resonance spectroscopy in IDHmutated patients with gliomas," Nature Medicine, vol. 18, no. 4, pp. 624-629, 2012.
113. M. Diehn, C. Nardini, D. S. Wang et al., "Identification of noninvasive imaging surrogates for brain tumor gene-expression modules," Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 13, pp. 5213-5218, 2008.
114. R. J. Young, A. Gupta, A. D. Shah et al., "Potential role of preoperative conventional MRI including diffusion measurements in assessing epidermal growth factor receptor gene amplification status in patients with glioblastoma," American Journal of Neuroradiology, vol. 34, no. 12, pp. 2271-2277, 2013.
115. M. C. Mabray, R. F. Barajas, and S. Cha, "Modern brain tumor imaging," Brain Tumor Research and Treatment, vol. 3, no. 1, pp. 8-23, 2015.
116. W. Kaspera, K. Majchrzak, B. Bobek-Billewicz et al., "Reoperations of patients with low-grade gliomas in eloquent or near eloquent brain areas," Neurologia i Neurochirurgia Polska, vol. 47, no. 2, pp. 116-125, 2013.
117. K. Majchrzak, W. Kaspera, B. Bobek-Billewicz et al., "The assessment of prognostic factors in surgical treatment of lowgrade gliomas: a prospective study," Clinical Neurology and Neurosurgery, vol. 114, no. 8, pp. 1135-1144, 2012.
118. A. Gupta, R. J. Young, A. D. Shah et al., "Pretreatment dynamic susceptibility contrast MRI perfusion in Glioblastoma: prediction of EGFR gene amplification," Clinical Neuroradiology, vol. 25, no. 2, pp. 143-150, 2014.
119. B. M. Ellingson, T. F. Cloughesy, W. B. Pope et al., "Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: a radiographic study in 358 de novo human glioblastomas," NeuroImage, vol. 59, no. 2, pp. 908-916, 2012.
120. P. Korfiatis, T. L. Kline, L. Coufalova et al., "MRI texture features as biomarkers to predict MGMT methylation status in glioblastomas," Medical Physics, vol. 43, no. 6, pp. 2835-2844, 2016.
121. V. A. Larsen, H. J. Simonsen, I. Law, H. B. W. Larsson, and A. E. Hansen, "Evaluation of dynamic contrast-enhanced T1- weighted perfusion MRI in the differentiation of tumor recurrence from radiation necrosis," Neuroradiology, vol. 55, no. 3, pp. 361-369, 2013.
122. W. B. Pope, X. J. Qiao, H. J. Kim et al., "Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study," Journal of Neuro-Oncology, vol. 108, no. 3, pp. 491-498, 2012.
123. B.M. Ellingson, T. F. Cloughesy, T. Zaw et al., "Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastoma," Neuro-Oncology, vol. 14, no. 3, pp. 333-343, 2012.
124. T. Singhal, T. K. Narayanan, M. P. Jacobs, C. Bal, and J. C. Mantil," 11C-methionine PET for grading and prognostication in gliomas: a comparison study with 18F-FDG PET and contrast enhancement on MRI," Journal of NuclearMedicine, vol. 53, no. 11, pp. 1709-1715, 2012.
125. G. Pöpperl, F. W. Kreth, J. H. Mehrkens et al., "FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading," European Journal of Nuclear Medicine and Molecular Imaging, vol. 34, no. 12, pp. 1933-1942, 2007.
126. S. Kim, J. K. Chung, S. H. Im et al., "11C-methionine PET as a prognostic marker in patients with glioma: comparison with 18F-FDG PET," European Journal of Nuclear Medicine and Molecular Imaging, vol. 32, no. 1, pp. 52-59, 2005.
127. D. Pauleit, F. Floeth, K. Hamacher et al., "O-(2-[18F]fluoroethyl)- L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas," Brain, vol. 128, no. 3, pp. 678-687, 2005.
128. B. J. Fueger, J. Czernin, T. Cloughesy et al., "Correlation of 6- 18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas," Journal of Nuclear Medicine, vol. 51, no. 10, pp. 1532-1538, 2010.
129. A. M. Spence, M. Muzi, K. R. Swanson et al., "Regional hypoxia in glioblastoma multiforme quantified with [18F] fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival," Clinical Cancer Research, vol. 14, no. 9, pp. 2623-2630, 2008.
130. L.W. Xu, K. K. Chow, M. Lim, and G. Li, "Current vaccine trials in glioblastoma: a review," Journal of Immunology Research, vol. 2014, Article ID796856, 10 pages, 2014.
131. T. Siegal, "Clinical impact of molecular biomarkers in gliomas," Journal of ClinicalNeuroscience, vol. 22, no. 3, pp. 437-444, 2015.
132. A. A. Brandes, E. Franceschi, A. Tosoni et al., "MGMTpromoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients," Journal of Clinical Oncology, vol. 26, no. 13, pp. 2192-2197, 2008.
133. H. Shao, J. Chung, L. Balaj et al., "Protein typing of circulating microvesicles allows real-timemonitoring of glioblastoma therapy," Nature Medicine, vol. 18, no. 12, pp. 1835-1840, 2012.
134. J. Skog, T. Würdinger, S. van Rijn et al., "Glioblastoma microvesicles transport RNAand proteins that promote tumour growth and provide diagnostic biomarkers," Nature Cell Biology, vol. 10, no. 12, pp. 1470-1476, 2008.
135. Y. Chen, F. Hu, Y. Zhou, W. Chen, H. Shao, and Y. Zhang, "MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-analysis," Archives of Medical Research, vol. 44, no. 4, pp. 281-290, 2013.
136. A. L. Rivera, C. E. Pelloski, M. R. Gilbert et al., "MGMT promotermethylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma," Neuro-Oncology, vol. 12, no. 2, pp. 116-121, 2010.
137. M. E. Hegi, L. Liu, J. G. Herman et al., "Correlation of O6- methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity," Journal of Clinical Oncology, vol. 26, no. 25, pp. 4189-4199, 2008.
138. M. A. Hammoud, R. Sawaya, W. Shi, P. F. Thall, and N. E. Leeds, "Prognostic significance of preoperative MRI scans in glioblastoma multiforme," Journal of Neuro-Oncology, vol. 27, no. 1, pp. 65-73, 1996.
139. C. X. Wu, G. S. Lin, Z. X. Lin et al., "Peritumoral edema on magnetic resonance imaging predicts a poor clinical outcome in malignant glioma," Oncology Letters, vol. 10, no. 5, pp. 2769- 2776, 2015.
140. W. Wick, C. Meisner, B. Hentschel et al., "Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation," Neurology, vol. 81, no. 17, pp. 1515- 1522, 2013.
141. M. Weller, R. Stupp, M. E. Hegi et al., "Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice," Neuro-Oncology, vol. 14, supplement 4, pp. iv100-iv108, 2012.